Seipel, K.; Graber, C.; Flückiger, L.; Bacher, U.; Pabst, T.
Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia. Int. J. Mol. Sci. 2021, 22, 8092.
https://doi.org/10.3390/ijms22158092
AMA Style
Seipel K, Graber C, Flückiger L, Bacher U, Pabst T.
Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences. 2021; 22(15):8092.
https://doi.org/10.3390/ijms22158092
Chicago/Turabian Style
Seipel, Katja, Carolyn Graber, Laura Flückiger, Ulrike Bacher, and Thomas Pabst.
2021. "Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia" International Journal of Molecular Sciences 22, no. 15: 8092.
https://doi.org/10.3390/ijms22158092
APA Style
Seipel, K., Graber, C., Flückiger, L., Bacher, U., & Pabst, T.
(2021). Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 22(15), 8092.
https://doi.org/10.3390/ijms22158092